Trial · NCT03500549
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Grams per deciliter (g/dL) | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP | Day 1 to Week 16 | The ITT set included all randomized subjects. | Percentage of subjects | NUMBER |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | 10^9 cells/ liter (L) | LEAST_SQUARES_MEAN |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Units (U)/L | LEAST_SQUARES_MEAN |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16 | Baseline and Week 16 | The ITT set included all randomized subjects. | Percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16 | Week 16 | The ITT set includes all randomized subjects. | Percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16 | Week 16 | The ITT set included all randomized subjects. | Percentage of subjects | NUMBER |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Micromole (μmol)/L | LEAST_SQUARES_MEAN |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | g/L | LEAST_SQUARES_MEAN |
| SECONDARY | LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | LS Mean Change From Baseline to Week 16 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Scale (QLQ-C30) Scores During the RCP | Baseline and Week 16 | The ITT set included all randomized subjects. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Total Number of PRBC Units Transfused During the RCP | Day 1 to Week 16 | The ITT set included all randomized subjects. | PRBC units | NUMBER |
| SECONDARY | Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period | Baseline and Week 48 | The ITT set included all randomized subjects. | g/dL | MEAN |
| SECONDARY | Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period | Week 17 and Week 48 | The ITT set included all randomized subjects. | g/dL | MEAN |
| SECONDARY | Mean Change From Baseline to Week 48 in ARC During the Treatment Period | Baseline and Week 48 | The ITT set included all randomized subjects. | 10^9 cells/L | MEAN |
| SECONDARY | Mean Change From Week 17 to Week 48 in ARC During the Open-label Period | Week 17 and Week 48 | The ITT set included all randomized subjects. | 10^9 cells/L | MEAN |
| SECONDARY | Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period | Baseline and Week 48 | The ITT set included all randomized subjects. | U/L | MEAN |
| SECONDARY | Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period | Week 17 and Week 48 | The ITT set included all randomized subjects. | U/L | MEAN |
| SECONDARY | Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period | Baseline and Week 48 | The ITT set included all randomized subjects. | Score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03500549/outcomes